VANCOUVER –

USA News Group

– Hope is on the horizon for

revolutionary treatments

meant to target solid tumors, which have historically been some the

toughest cancers to treat

. Beyond extending life expectancy, the incentive to tackle this form of cancer is enormous. The Global Solid Tumor Therapeutics Market is one of the fastest growing sectors in immunology, projected to grow at a high

CAGR of 16%

through to 2029, with expectations to reach

US$424.6 billion by 2027

. Working towards new forms of treatment are a series of biotech developers, including

O


ncolytics Biotech Inc.

(NASDAQ:ONCY) (TSX:ONC),

Gilead Sciences, Inc.

(NASDAQ:GILD),

Novartis AG

(NYSE:NVS),

Bristol-Myers Squibb Company

(NYSE:BMY), and

BioNTech SE

(NASDAQ:BNTX).

Among the breakthrough treatments on the horizon are those involving

CAR T-cell therapy

, where a patient’s T cells are altered in a laboratory to attack cancer cells. Recently,

researchers at Mayo Clinic

reported they’ve devised an immunotherapy technique by loading CAR T cells with

oncolytic viruses

to treat solid tumors.

One platform proving to be synergistic with CAR T therapies involves a non-pathogenic double-stranded RNA virus known as reovirus. Developed under its trade name

pelareorep

, proprietors

O


ncolytics Biotech Inc.

(NASDAQ:ONCY) (TSX:ONC) recently announced the publication of

preclinical data

demonstrating oncolytic virus-mediated synergistic anti-cancer activity when combined with CAR T cell therapy in solid tumors.

The results were published in a paper in


Science Translational Medicine


in collaboration with researchers at several prestigious institutions, including the Mayo Clinic and Duke University.

“Having these results published in such a high-impact journal provides important external validation of their significance,” said Thomas Heineman, M.D., Ph.D., Chief Medical Officer of

Oncolytics Biotech

. “This is a powerful finding that, if translated to the clinic, could significantly improve the prognosis of patients with a variety of highly prevalent cancers by providing a novel and potentially durable treatment option.”

Preclinical studies published in the paper evaluated the persistence and efficacy of pelareorep-loaded CAR T cells (“CAR/Pela therapy”) in multiple murine solid tumor models, including showing the persistence and anti-cancer activity of CAR T cells improving drastically, and statistically significant survival benefits in murine skin and brain cancer models.

“These exciting results are an excellent example of how we are leveraging collaborations with key opinion leaders and premier research institutions to broaden pelareorep’s potential therapeutic impact,” said Dr. Matt Coffey, President and CEO of

Oncolytics Biotech

and co-author of the paper. “As we pursue this opportunity moving forward, we intend to utilize relationships with academic or industry partners so that we can continue to execute on our clinical and corporate objectives with efficiency.”

In order to meet the growing patient demand for these new types of cancer, the US FDA recently

approved commercial production

at a new state-of-the-art Maryland facility owned and operated by

Kite

, a subsidiary of

Gilead Sciences, Inc.

(NASDAQ:GILD).

“The FDA approval of our Maryland site marks an important milestone within our global CAR T-cell therapy manufacturing network, and will enable us to significantly expand our production capacity and further strengthen our ability to meet the needs of people living with difficult-to-treat blood cancers,” said Christi Shaw, CEO of

Kite

.

The site is set to produce

Kite’s

FDA approved CAR T-cell therapy—in this case used to treat blood cancer. CAR T-cell therapies are individually manufactured for each patient using their own T-cells extracted from their white blood cells.

Kite

therapies are available at over 275 authorized treatment centers (ATCs), or hospitals around the world, including more than

110 leading cancer hospitals

in the U.S.

When

Gilead

identified the potential for

Kite’s

technology, it agreed to acquire the California-based

Kite

for

nearly $12 billion in 2017

.

However, one of the candidates

Kite

was developing involved solid tumors, which was sold to

BioNTech SE

(NASDAQ:BNTX) in July of 2021. Among the

assets sold

to

BioNTech

were

Kite’s

neoantigen TCR cell therapy R&D platform and manufacturing facility in Gaithersburg, Maryland.

Flash forward to 2022, and in a clinical trial sponsored by

BioNTech’s

subsidiary BioNTech Cell & Gene Therapies, their new CAR T-cell therapy has shown an acceptable safety profile and demonstrated

early signs of efficacy

as a monotherapy and in combination with an mRNA vaccine in patients with solid tumors.

“We have five ongoing randomized Phase 2 trials across a range of solid tumor indications,” commented

BioNTech

co-founder and CEO, Ugur Sahin during a

recent earnings call

. “This includes our FixVac, iNeST, Bispecific antibody program… [and] includes the cell therapy facility we acquired from

Kite

as well as the

Medigene

asset acquisition and discovery collaboration that further expanded our TCR pipeline.”

Sahin went on to state that his company believes TCR (T-Cell Receptor therapy) “has the potential to be best-in-class for a range of solid tumors.”

Novartis AG

(NYSE:NVS) recently presented

early clinical data

for its unique KRASG12C inhibitor. The data demonstrated anti-tumor activity, high systemic exposure at its recommended dose, and a favorable safety profile based on initial clinical data in patients with

KRAS G12C

-mutated solid tumors.

The company’s proposed treatment KontRASt-01 (NCT04699188) is a phase Ib/II open-label, multi-center, dose escalation study of JDQ443, in patients with advanced solid tumors harboring the

KRAS G12C

mutation, including NSCLC and colorectal cancer.

“After decades without a breakthrough, we as an industry are entering a transformative era in targeted treatment for

KRAS-mutated

cancers,” said Jeff Legos, Executive Vice President, Global Head of Oncology & Hematology Development at

Novartis

. “Today’s preliminary data are an encouraging signal that we are on the right path as we continue to investigate single-agent and multiple combination strategies designed to enhance efficacy of G12C targeted therapy and improve outcomes of patients with

KRAS G12C

-driven cancers.”

In order to obtain even more

advance research

into options for solid tumor treatment,

Bristol-Myers Squibb Company

(NYSE:BMY) has partnered with

Roche

to leverage the capabilities of artificial intelligence and computation technology in digital pathology. The goal of the projects is to generate information that can be used to advance personalized solid tumor treatment options and aid in more accurate cancer diagnoses.

“We believe digital methods will bring significant improvements in standardization and interpretation of tissue-based assays and will enable broader access to tissue-based assays,” said Sarah Hersey, the vice president for the translational sciences and diagnostics arm of

Bristol Myers Squibb

. “The ability to more deeply interrogate images will present opportunities to better understand disease biology, potentially leading to expanded and improved drug development options and ultimately highly effective patient selection strategies.”

Article Source: :

DISCLAIMER:


Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.